Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Carfilzomib combinations in ENDEAVOR and FORTE

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Deep molecular response to gilteritinib in CHRYSALIS trial

Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern...

Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA

$Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )$

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed...

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA

$Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )$

Clinical potential of trastuzumab biosimilar CTP6

Prof Francisco Esteva - NYU Langone Medical Center, New York, USA

Clinical potential of trastuzumab biosimilar CTP6 ( Prof Francisco Esteva - NYU Langone Medical Center, New York, USA )

Updates in melanoma: Treating BRAF and brain metastases

Prof Georgina Long - University of Sydney, Sydney, Australia

Updates in melanoma: Treating BRAF and brain metastases ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Alectinib eclipses crizotinib for ALK positive lung cancer

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Alectinib eclipses crizotinib for ALK positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Targeted sequencing in endocrine refractory breast cancer

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

$Targeted sequencing in endocrine refractory breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )$

Results from the APHINITY trial of two HER2 targeted agents with chemo

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Results from the APHINITY trial of two HER2 targeted agents with chemo ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Nivolumab and ipilimumab for metastatic sarcoma

Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA

Nivolumab and ipilimumab for metastatic sarcoma ( Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA )

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain

Dose escalation results of ceritinib and nivolumab for ALK NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain )

Phase III results of olaparib for BRCA breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Phase III results of olaparib for BRCA breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

More from ecancer